Express Pharma

US court rules in favour of DRL on generic Suboxone

3

A patent infringement case was filed by pharma giant Indivior on selling generic version of Suboxone

Dr Reddy’s Laboratories (DRL) said a court in the US has given a ruling in favour of it in a patent infringement case filed by pharma giant Indivior on selling generic version of Suboxone a sublingual film in the American market.

According to a press release issued by the Hyderabad-based drug maker, the United States Court of Appeals for the Federal Circuit concluded that Indivior had not shown that it is likely to succeed on the merits of its infringement case. It also said this decision vacates a District Court”s preliminary injunction that had prohibited DRL from selling its generic version of Suboxone (buprenorphine and naloxone). Buprenorphine and naloxone are used to treat adults with opioid dependence or addiction. As a result of today’s ruling, DRL will resume its launch activities as soon as it is permitted, it said.

According to market reports, suboxone had sales of around $1.86 billion in the US for the 12 months ended April. A company spokesperson said, “We are pleased with the decision of the appellate court in DRL’s favour, vacating the preliminary injunction that had prevented DRL’s from bringing this important drug to the public. We are committed to providing affordable and innovative medicines that address the unmet and under-met needs of patients around the world and in particular look forward to taking the lead in helping to fight Opioid Use Disorder.”

In June, the US Food and Drug Administration (US FDA) approved DRL Buprenorphine and Naloxone Sublingual Film, in four strengths including 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, and 12 mg/3 mg, for sale in the US market. The product was launched immediately after approval, with sales and commercialisation activities halted as a result of a court-imposed temporary restraining order against DRL. The TRO did not include a prohibition on commercial manufacturing of the product.

 

 

Comments are closed.